Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug

Published 13/03/2023, 15:40
Updated 13/03/2023, 15:40
© Reuters.

© Reuters.

By Scott Kanowsky 

Investing.com -- Sanofi SA (EPA:SASY) agreed to purchase US-based pharmaceutical firm Provention Bio (NASDAQ:PRVB) in a deal worth approximately $2.9 billion, as the French drugmaker looks to boost its general medicines portfolio with a US-approved type 1 diabetes drug.

In a statement, Sanofi said the deal, which is expected to close in the second quarter of 2023, will give it full ownership of TZIELD, a treatment used to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 and older.

The move also helps address recent investor criticism over Sanofi's pipeline of drugs, although growth in the company's asthma and eczema medicines has remained strong.

Sanofi executive vice president Olivier Charmeil said the agreement, which will see it buy Provention Bio for $25 per share, builds on a previous partnership between the two groups.

"By coupling Provention Bio’s transformative innovation with Sanofi's expertise, we aim to bring life-changing benefits to people at risk of developing Stage 3 type 1 diabetes. Any additional indications, approvals and pipeline assets only serve to further our excitement," Charmeil added.

Provention stock jumped by more than 258% following the announcement, while Paris-listed shares in Sanofi edged lower.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.